TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund.
CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor
Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.
The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto.
Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in…
MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to…
TORONTO (October 14, 2010) – Of the approximately 300 million people around the world who are diabetics, 45 million of them develop foot ulcers that bleed – and the infection from those ulcers can spread.
Working to halt this is Dr. Ping Lee, a professor at the University of Toronto’s (U of T) Leslie Dan Faculty of Pharmacy and GlaxoSmithKline chair in Pharmaceutics and Drug Delivery. He and his team have created a new sustained‐release form of nitric oxide (NO) that can not only stop the infections at wound sites, but also has the potential to speed up wound‐healing.
Still, the technology may have stayed on the shelf, even with three years worth of data demonstrating therapeutic relevance. The ultimate success of the technology is due to an effective collaboration between Dr. Lee, the Innovations and Partnerships Office (IPO) at U of T and MaRS Innovation (MI). Lee worked with IPO and MI to formulate a development plan in consultation with numerous industry advisors.
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MaRS Innovation.